Research progress on target therapy in advanced non-small cell lung cancer
- VernacularTitle:晚期非小细胞肺癌的靶向治疗研究进展
- Author:
Weitao MAN
;
Yong HUANG
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
molecular targeted drugs;
research progress
- From:
China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
As the efficacies of chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC) have reached a plateau, the molecularly targeted therapy becomes a new method to improve curative effects.The molecular targeted drugs include epidermal growth factor receptor inhibitors, anti-angiogenesis drugs, etc.As one of the representative drugs of EGFR inhibitors, Gefitinib, has a low clinical benefit index.Erlotinib, the first EGFRTK inhibitor, can enhance the survival of patients, and may serve as a potential choice for the first-line treatment of advanced NSCLC.Bevacizumab combined with chemotherapy has shown a favorable clinical effect in the first-line treatment, and it is also the first anti-angiogenesis drug approved by the FDA that can be used in cancer treatment.These drugs, together with clinical and experimental progress in many other targeted drugs, have shown a favorable prospect for targeted drugs in the treatment of advanced non-small cell lung cancer.
